stephen lyle

Stage 1 Ventures LLC (Stage 1 Ventures) is a venture capital firm founded in 2006 by David William Baum. The firm is headquartered in Miami, Florida.

Kew, Inc. provides oncology services. It provides multiple services to oncologists to assist in treatment decisions for cancer patients and offers genomic testing for patient tumor samples and genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways. The company was founded by Richard Bohmer, Viren Mehta, Clayton Matt Christensen, Jeffrey Elton, Mason Freeman, John P. Glaser, H. Robert Horvitz, Bruce Johnson, Kathy Behrens Wilsey and Raju S. Kucherlapat in 2009 and is headquartered in Cambridge, MA.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.